T1	Participants 224 347	patients with epithelial ovarian carcinoma that recurred after or didn't respond to first-line, platinum-based chemotherapy
T2	Participants 370 417	Patients with measurable and assessable disease
T3	Participants 567 679	Patients were stratified prospectively for platinum sensitivity and for the presence or absence of bulky disease
T4	Participants 689 712	A total of 474 patients
